{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chang W"],"funding":["Intramural NIH HHS"],"pagination":["3810-20"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4970946"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(15)"],"pubmed_abstract":["Purpose
We undertook a multidimensional clinical genomics study of children and adolescent young adults with relapsed and refractory cancers to determine the feasibility of genome-guided precision therapy.Experimental design
Patients with non-central nervous system solid tumors underwent a combination of whole exome sequencing (WES), whole transcriptome sequencing (WTS), and high-density single-nucleotide polymorphism array analysis of the tumor, with WES of matched germline DNA. Clinically actionable alterations were identified as a reportable germline mutation, a diagnosis change, or a somatic event (including a single nucleotide variant, an indel, an amplification, a deletion, or a fusion gene), which could be targeted with drugs in existing clinical trials or with FDA-a"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research."],"pmcid":["PMC4970946"],"funding_grant_id":["ZIA BC010998","ZIA BC011002"],"pubmed_authors":["Gryder B","Wen X","Patidar R","Widemann BC","Lin JC","Brohl AS","Badgett TC","Shivaprasad N","Miettinen M","Shern JF","Zhang S","Chang W","Hartman KR","Kaplan RN","Song YK","Khan J","Calzone KA","Yohe ME","Wei JS","Trahair TN","Merchant MS","Sindiri S","League-Pascual JC"],"additional_accession":[]},"is_claimable":false,"name":"MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research.","description":"Purpose
We undertook a multidimensional clinical genomics study of children and adolescent young adults with relapsed and refractory cancers to determine the feasibility of genome-guided precision therapy.Experimental design
Patients with non-central nervous system solid tumors underwent a combination of whole exome sequencing (WES), whole transcriptome sequencing (WTS), and high-density single-nucleotide polymorphism array analysis of the tumor, with WES of matched germline DNA. Clinically actionable alterations were identified as a reportable germline mutation, a diagnosis change, or a somatic event (including a single nucleotide variant, an indel, an amplification, a deletion, or a fusion gene), which could be targeted with drugs in existing clinical trials or with FDA-a","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Aug","modification":"2026-05-04T10:35:48.769Z","creation":"2019-03-27T02:19:45Z"},"accession":"S-EPMC4970946","cross_references":{"pubmed":["26994145"],"doi":["10.1158/1078-0432.ccr-15-2717","10.1158/1078-0432.CCR-15-2717"]}}